

## Standing Order for Administering Pneumococcal Vaccine (Adult)

**Purpose:** To reduce morbidity and mortality from pneumococcal disease by vaccinating all individuals who meet the criteria established by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP), the Food and Drug Administration (FDA) product labeling, and the Department of Defense (DoD).

**Policy:** Under this standing order, eligible health care professionals working within their scope of practice may vaccinate patients who meet the criteria below.

### Procedure:

1. Identify persons  $\geq 19$  years of age in need of vaccination against pneumococcus infection based on the [following criteria](#):
  - $\geq 65$  years of age
  - 19 - 64 years of age with no or unknown history of receipt of an adult dose of pneumococcal vaccine with any of the following risk factors:
    - Alcoholism or cigarette smoking
    - Asplenia (congenital or acquired)
    - Cerebrospinal fluid leak
    - Chronic heart, liver, or lung disease (e.g., heart failure, cardiomyopathies, cirrhosis, chronic obstructive pulmonary disease, emphysema, and asthma)
    - Chronic renal failure or nephrotic syndrome
    - Cochlear implant
    - Diabetes mellitus
    - Generalized malignancy (e.g., Hodgkin disease, leukemia, lymphoma, multiple myeloma)
    - [iatrogenic immunosuppression](#) (e.g., treatment with immunosuppressive drugs [including long-term systemic steroids], biologics, and radiation therapy)
    - Immunodeficiencies (congenital or acquired, e.g., HIV, B or T-lymphocyte deficiency, complement deficiencies, and phagocytic disorders [excluding chronic granulomatous disease])
    - Sickle cell disease (SCD) or other hemoglobinopathies
    - Solid organ transplant
2. Using [DD Form 3111](#), screen all patients for contraindications and precautions to pneumococcal vaccine:

### Contraindications:

- History of a serious reaction (e.g., anaphylaxis) after a previous dose of pneumococcal vaccine, to any vaccine containing diphtheria toxoid, or to a vaccine component (including yeast)
- For information on vaccine components, refer to the package insert for [PCV15](#), [PCV 20](#), [PPSV23](#), or [The CDC Pink Book Appendix B](#).

### Precautions:

- Moderate or severe acute illness with or without fever
- Syncope (fainting) can occur in association with administration of injectable vaccines. Have procedures in place to avoid a falling injury (e.g., 15-minute observation after administration) and to restore cerebral perfusion.
- For questions or concerns, consider consulting the DHA Immunization Healthcare Support Center at (877) 438-8222, Option 1 or DSN 761-4245.

3. Provide all patients (or their parent/legal representative) with a copy of the most current federal [Vaccine Information Statement \(VIS\)](#). Provide non-English speaking patients with a copy of the VIS in their native language, if available and preferred.
4. Provide vaccine as follows:
  - Administer 0.5 mL of the appropriate pneumococcal vaccine according to Tables 1, 2, & 3.
  - PCV15 and PCV20 are given intramuscularly (IM).
  - PPSV23 may be given IM or subcutaneously (SC).
  - Individuals with anatomic or functional asplenia and/or HIV: PCV vaccines and MenACYW-D (Menactra) should not be given concomitantly. Administer Menactra  $\geq$  4 weeks after completion of all PCV doses.

<b>TABLE 1. IM Needle Length and Injection Site Guide</b>		
<ul style="list-style-type: none"> <li>• Use a 22 – 25-gauge needle</li> <li>• Choose needle gauge and length appropriate to the patient’s age, sex, and weight</li> </ul>		
<b>Patient age</b>	<b>Needle Length</b>	<b>Injection Site</b>
Children & Adolescents, 11-18 years	5/8*-1 inch (16-25 mm)	Deltoid muscle of arm <sup>†</sup>
	1-1.5 inches (25-38 mm)	Anterolateral thigh
<b>Adults (<math>\geq</math> 19 years)</b>		
Men and women, <60 kg (130 lbs)	5/8*-1 inch (16-25 mm)	Deltoid muscle of arm
Men and women, 60-70 kg (130-152 lbs)	1 inch (25 mm)	
Men, 70-118 kg (152-260 lbs)	1-1.5 inches (25-38 mm)	
Women, 70-90 kg (152-200 lbs)		
Men, >118 kg (260 lbs)	1.5 inches (38 mm)	
Women, >90 kg (200 lbs)		
Men and women, any weight	1*-1.5 inches (25-38 mm)	Anterolateral thigh

Adapted from the CDC General Best Practice Guidelines: <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html>.

\* If skin is stretched tightly and subcutaneous tissues are not bunched.

<sup>†</sup> Preferred site.

<b>TABLE 2. SC Needle Length and Injection Site Guide</b>	
<ul style="list-style-type: none"> <li>• Use a 5/8 inch 23 – 25-gauge needle</li> </ul>	
<b>Patient age</b>	<b>Injection Site</b>
Adults $\geq$ 18 years	Fatty tissue over triceps*
	Fatty tissue over anterolateral thigh

Adapted from the CDC General Best Practice Guidelines: <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html>.


\* Preferred site.

**TABLE 3. Pneumococcal Vaccine Schedule (Adult)**

Age ≥ 65 years: all patients  
 Age 19-64 years: only with risk factors\*\*†

**Do not give pneumococcal conjugate (PCV) and pneumococcal polysaccharide (PPSV) vaccine at the same visit.**

**Unknown or no prior doses of PCV or PPSV:**



**Previously received only PCV13:**



**Previously received only PPSV23:**



**Previously received PCV13 and PPSV23 (in any order):**



*Other risk factors:	†Highest risk:	
<ul style="list-style-type: none"> <li>Alcoholism</li> <li>Cigarette smoking</li> <li>Chronic heart, liver, or lung disease</li> <li>Diabetes</li> </ul>	<ul style="list-style-type: none"> <li>Asplenia</li> <li>Cerebrospinal fluid leak</li> <li>Chronic renal failure</li> <li>Cochlear implant</li> <li>Generalized malignancy</li> <li>HIV infection</li> <li>Hodgkin disease</li> <li>Iatrogenic immunosuppression</li> </ul>	<ul style="list-style-type: none"> <li>Immunodeficiency</li> <li>Leukemia</li> <li>Lymphoma</li> <li>Multiple myeloma</li> <li>Nephrotic syndrome</li> <li>SCD or other hemoglobinopathies</li> <li>Solid organ transplant</li> </ul>

Adapted from California Department of Public Health, Immunization Branch #IMM-1152 (3/23)

- Document all immunizations administered in the patient's electronic health record and the appropriate immunization tracking system. Include date, immunization given, dose, anatomical location of administration, lot number, manufacturer, Vaccine Information Sheet (VIS) date, and the identification of the person administering the vaccine. If vaccine was not given, record the reason for non-receipt.
- Be prepared to manage a medical emergency related to the administration of vaccines by having a written emergency medical protocol available, as well as equipment and medications.
- Adverse events occurring after administration of any vaccine should be reported to the Vaccine Adverse Event Reporting System (VAERS) online at <https://vaers.hhs.gov>. Additional VAERS information is also available by telephone (800-822-7967).
- This standing order shall remain in effect for all patients of the \_\_\_\_\_ until rescinded and/or upon a change in the Medical Director, whichever is earlier.

\_\_\_\_\_  
 Medical Director's Signature

\_\_\_\_\_  
 Date